Texas Heart Takes to the CoreoGraft
Source: Daniel Carlson for Streetwise Reports  (10/10/18)
Daniel Carlson of Tailwinds Research profiles Hancock Jaffe Laboratories, which is partnering with the Texas Heart Institute to further develop an innovative graft designed for use in coronary bypass surgery. More >

Developer of Nitric Oxide Delivery Devices Rebrands to Focus on Leading Advancements
Source: Streetwise Reports  (10/9/18)
This Utah-based company rolled out an online campaign that highlights its strategic repositioning. More >

DURECT Receives Return on Schizophrenia Drug Approval
Source: Streetwise Reports  (10/3/18)
A new, once-monthly injectable treatment for schizophrenia uses patents of a small-cap, U.S.-based pharmaceutical firm. More >

Company with Cancer Radiotherapy Grows Revenue for Six Consecutive Quarters
Source: Streetwise Reports  (10/3/18)
An H.C. Wainwright & Co. report reviewed this company's Q4/18 earnings and opportunities for increasing it. More >

Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm
Source: Streetwise Reports  (9/26/18)
This regenerative medicine company moves one step closer to commercialization of its cell therapies in East Asia. More >

NIH Selects Biopharma's Lead Asset for Commercialization Accelerator Program
Source: Streetwise Reports  (9/26/18)
A Maxim Group analyst reported on news and upcoming catalysts for this late-stage drug developer. More >

Biotech's Preliminary Immunotherapy Data 'Positive,' Earns Coverage in Medical Journal
Source: Streetwise Reports  (9/26/18)
An H.C. Wainwright & Co. report reviewed both the results and an "unusual" highlight from this firm's trial in head-and-neck cancer. More >

Life Science Company Sells Large Order of Non-Antibiotic Growth Promoter for Livestock
Source: Streetwise Reports  (9/25/18)
This is the second large shipment to the Philippine distributor. More >

This Company Has Better Numbers than Tilray at 1/25th the Price
Source: Fincom Investment Partners for Streetwise Reports  (9/24/18)
Tilray's wild fluctuations have grabbed the headlines the past few days, but Fincom Investment Partners profiles a rapidly emerging player in the cannabis realm that the firm believes has much more to offer. More >

Medical Use of Nitric Oxide Expands as Costs Come Down
Source: Streetwise Reports  (9/19/18)
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system. More >

Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside'
Source: Streetwise Reports  (9/19/18)
An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm. More >

Cancer Vaccine Developer Expands Its Collaboration with Merck
Source: Streetwise Reports  (9/19/18)
A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner. More >

U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan
Source: Streetwise Reports  (9/18/18)
Permission has been obtained to distribute time-release capsules. More >

Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment
Source: Daniel Carlson for Streetwise Reports  (9/14/18)
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. More >

Canadian Biopharma to Outlicense Pain Drug to South Korean Firm
Source: Streetwise Reports  (9/12/18)
An Echelon Wealth Partners report discussed the deal terms.
More >

Biopharma's Positive FDA Meeting Outlines Path Forward for Trial
Source: Streetwise Reports  (9/11/18)
A ROTH Capital Partners note explained the outcome of the tête-a-tête and its implications.

More >

Final Approval of Biopharma's Lead Candidate Both Likely and Imminent
Source: Streetwise Reports  (9/5/18)
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. More >

Drug Company Receives $5 Million Milestone Payment
Source: Streetwise Reports  (8/31/18)
Company entitled to receive quarterly earn-out payments from patent agreement. More >

Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment
Source: Streetwise Reports  (8/29/18)
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. More >

Oncology-Focused Biotech Receives Orphan Status for AML Drug
Source: Streetwise Reports  (8/29/18)
An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates. More >

Investor Opportunity Arises from Biopharma's Share Price Weakness on Competitor News
Source: Streetwise Reports  (8/29/18)
An analyst discussed the implications to this firm of a competitive product's advancement.
More >

As Nitric Oxide Comes Off Patent, Lower-Cost Options for Life Saving Drug Becoming Possible
Source: Streetwise Reports  (8/22/18)
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available. More >

Coverage Initiated on Developer of Brachytherapy Products for Cancer Treatment
Source: Streetwise Reports  (8/22/18)
H.C. Wainwright & Co. analyst Jason Kolbert provided the rationale for investment in this company. More >

Biotech Marks Progress on Programs for Cancer, Infectious Diseases
Source: Streetwise Reports  (8/15/18)
This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst. More >

Biopharma Signs Multimillion-Dollar Deal for Key Products in China
Source: Streetwise Reports  (8/8/18)
An H.C. Wainwright & Co. report reviewed the arrangement. More >